| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
GI 181771 manufacturers
- GI 181771
-
- $1380.00
-
2026-05-11
- CAS:305366-98-7
- Purity: 95.02%
- Supply Ability: 10g
|
| | GI 181771 Basic information |
| Product Name: | GI 181771 | | Synonyms: | GI 181771;CABBMMXFOOZVMS-PMERELPUSA-N;Benzoic acid, 3-[[[[(3S)-2,3,4,5-tetrahydro-1-[2-[(1-methylethyl)phenylamino]-2-oxoethyl]-2,4-dioxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]amino]carbonyl]amino]-;GI181771X;3-[[[[(3S)-2,3,4,5-tetrahydro-1-[2-[(1-methylethyl) phenylamino]-2-oxoethyl]-2,4-dioxo-5-phenyl-1H-1,5-benzodiazepin-3-yl] amino] carbonyl] amino] benzoic acid | | CAS: | 305366-98-7 | | MF: | C34H31N5O6 | | MW: | 605.65 | | EINECS: | | | Product Categories: | | | Mol File: | 305366-98-7.mol |  |
| | GI 181771 Chemical Properties |
| Boiling point | 894.3±65.0 °C(Predicted) | | density | 1.41±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 4.16±0.10(Predicted) |
| | GI 181771 Usage And Synthesis |
| Uses | GI 181771 is a cholecystokinin 1 receptor agonist investigated for the treatment of obesity. | | References | [1] Myer JR, et al. Species- and dose-specific pancreatic responses and progression in single- and repeat-dose studies with GI181771X: a novel cholecystokinin 1 receptor agonist in mice, rats, and monkeys. Toxicol Pathol. 2014 Jan;42(1):260-74. DOI:10.1177/0192623313506792
[2] Roses AD, et al. Stimulation of cholecystokinin-A receptors with Gl181771X: a failed clinical trial that did not test the pharmacogenetic hypothesis for reduction of food intake. Clin Pharmacol Ther. 2009 Apr;85(4):362-5. DOI:10.1038/clpt.2008.192 |
| | GI 181771 Preparation Products And Raw materials |
|